CSF1 Is a Novel p53 Target Gene Whose Protein Product Functions in a Feed-Forward Manner to Suppress Apoptosis and Enhance p53-Mediated Growth Arrest

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Azzam, Gregory ^a   Wang, Xuting ^b   Bell, Douglas ^b   Murphy, Maureen E ^a  

^a WISTAR INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; PROTEIN P72;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BINDING SITE; CDKN1A GENE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CSF1 GENE; CSF1R GENE; EPITHELIUM TUMOR; FEEDBACK SYSTEM; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RADIATION RESPONSE; RNA ISOLATION; SENESCENCE; SIGNAL TRANSDUCTION; THYMOCYTE; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; ARGININE; CELL DIVISION; GENES, P53; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; PROLINE; RADIATION TOLERANCE; TRANSCRIPTIONAL ACTIVATION;

EID: 84883312938     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074297     Document Type: Article

References (45)

1. Gottlieb TM, Oren M, (1996) p53 in growth control and neoplasia. Biochim Biophys Acta 1287: 77-102.
2. Komarova EA, Chernov MV, Franks R, Wang K, Armin G, et al. (1997) Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 16: 1391-1400.
3. MacCallum DE, Hupp TR, Midgley CA, Stuart D, Campbell SJ, et al. (1996) The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 13: 2575-2587.
4. Chen X, Ko LJ, Jayaraman L, Prives C, (1996) p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 10: 2438-2451.
5. Chipuk JE, Green DR, (2006) Dissecting p53-dependent apoptosis. Cell Death Differ 13: 994-1002.
6. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, et al. (2006) Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24: 841-851.
7. Tang Y, Luo J, Zhang W, Gu W, (2006) Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 24: 827-839.
8. Pietsch EC, Sykes SM, McMahon SB, Murphy ME, (2008) The p53 family and programmed cell death. Oncogene 27: 6507-6521.
9. Canman CE, Gilmer TM, Coutts SB, Kastan MB, (1995) Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 9: 600-611.
10. Guillouf C, Grana X, Selvakumaran M, De Luca A, Giordano A, et al. (1995) Dissection of the genetic programs of p53-mediated G1 growth arrest and apoptosis: blocking p53-induced apoptosis unmasks G1 arrest. Blood 85: 2691-2698.
11. Dumont P, Leu JI, Della Pietra AC, (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365.
12. Jeong BS, Hu W, Belyi V, Rabadan R, Levine AJ, (2010) Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. FASEB J 24: 1347-1353.
13. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, et al. (2004) Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23: 3328-3337.
14. Salvioli S, Bonafe M, Barbi C, Storci G, Trapassi C, et al. (2005) p53 codon 72 alleles influence the response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1. Cell Cycle 4: 1264-1271.
15. Frank AK, Leu JI, Zhou Y, Devarajan K, Nedelko T, et al. (2011) The codon 72 polymorphism of p53 regulates interaction with NF-kB and transactivation of genes involved in immunity and inflammation. Mol Cell Biol 31: 1201-1213.
16. den Reijer PM, Maier AB, Westendorp RG, van Heemst D, (2008) Influence of the TP53 codon 72 polymorphism on the cellular responses to X-irradiation in fibroblasts from nonagenarians. Mech Ageing Dev 129: 175-182.
17. Bonafe M, Olivieri F, Mari D, Baggio G, Mattace R, et al. (1999) P53 codon 72 polymorphism and longevity: additional data on centenarians from continental Italy and Sardinia. Am J Hum Genet 65: 1782-1785.
18. Zhu F, Dolle ME, Berton TR, Kuiper RV, Capps C, et al. (2010) Mouse models for the p53 R72P polymorphism mimic human phenotypes. Cancer Res 70: 5851-5859.
19. Azzam GA, Frank AK, Hollstein M, Murphy ME, (2011) Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model. Cell Cycle 10: 1352-1355.
20. Pietsch EC, Humbey O, Murphy ME, (2006) Polymorphisms in the p53 pathway. Oncogene 25: 1602-1611.
21. Whibley C, Pharoah PD, Hollstein M, (2009) p53 polymorphisms: cancer implications. Nat Rev Cancer 9: 95-107.
22. Burgdorf KS, Grarup N, Justesen JM, Harder MN, Witte DR, et al. (2011) Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans. PLoS One 6: e15813.
23. Gaulton KJ, Willer CJ, Li Y, Scott LJ, Conneely KN, et al. (2008) Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes. Diabetes 57: 3136-3144.
24. Vietri MT, Riegler G, Ursillo A, Caserta L, Cioffi M, et al. (2007) p53 codon 72 polymorphism in patients affected with ulcerative colitis. J Gastroenterol 42: 456-460.
25. Vaji S, Salehi Z, Aminian K, (2011) Association of p53 codon 72 genetic polymorphism with the risk of ulcerative colitis in northern Iran. Int J Colorectal Dis 26: 235-238.
26. Eren F, Akkiprik M, Atug O, Sonmez O, Tahan G, et al. (2010) R72P polymorphism of TP53 in ulcerative colitis patients is associated with the incidence of colectomy, use of steroids and the presence of a positive family history. Pathol Oncol Res 16: 563-568.
27. Bandele OJ, Wang X, Campbell MR, Pittman GS, Bell DA, (2011) Human single-nucleotide polymorphisms alter p53 sequence-specific binding at gene regulatory elements. Nucleic Acids Res 39: 178-189.
28. Smeenk L, van Heeringen SJ, Koeppel M, Gilbert B, Janssen-Megens E, et al. (2011) Role of p53 serine 46 in p53 target gene regulation. PLoS One 6: e17574.
29. Xue W, Zender L, Miething C, Dickins RA, Hernando E, et al. (2007) Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656-660.
30. Kacinski BM, (1997) CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol Reprod Dev 46: 71-74.
31. Kacinski BM, Rodov S, Sapi E, (1999) Signal transduction pathways regulated by CSF-1 receptors modulate the in vitro radiosensitivity of mammary epithelial cells. Int J Radiat Oncol Biol Phys 45: 969-973.
32. Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML, (1997) Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res 3: 999-1007.
33. Chitu V, Stanley ER, (2006) Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol 18: 39-48.
34. Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, et al. (1994) Is p53 polymorphism maintained by natural selection? Hum Hered 44: 266-270.
35. Luo JL, Yang Q, Tong WM, Hergenhahn M, Wang ZQ, et al. (2001) Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20: 320-328.
36. Jaworski M, Hailfinger S, Buchmann A, Hergenhahn M, Hollstein M, et al. (2005) Human p53 knock-in (hupki) mice do not differ in liver tumor response from their counterparts with murine p53. Carcinogenesis 26: 1829-1834.
37. Liu Z, Muehlbauer KR, Schmeiser HH, Hergenhahn M, Belharazem D, et al. (2005) p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res 65: 2583-2587.
38. Luo JL, Tong WM, Yoon JH, Hergenhahn M, Koomagi R, et al. (2001) UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin. Cancer Res 61: 8158-8163.
39. Maher MG, Sapi E, Turner B, Gumbs A, Perrotta PL, et al. (1998) Prognostic significance of colony-stimulating factor receptor expression in ipsilateral breast cancer recurrence. Clin Cancer Res 4: 1851-1856.
40. Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, et al. (2004) Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 10: 173-177.
41. Cattelani S, Ferrari-Amorotti G, Galavotti S, Defferrari R, Tanno B, et al. (2012) The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform. Neoplasia 14: 634-643.
42. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
43. Wang X, Tomso DJ, Chorley BN, Cho HY, Cheung VG, et al. (2007) Identification of polymorphic antioxidant response elements in the human genome. Hum Mol Genet 16: 1188-1200.
44. Wasserman WW, Sandelin A, (2004) Applied bioinformatics for the identification of regulatory elements. Nat Rev Genet 5: 276-287.
45. Valouev A, Johnson DS, Sundquist A, Medina C, Anton E, et al. (2008) Genome-wide analysis of transcription factor binding sites based on ChIP-Seq data. Nat Methods 5: 829-834.